Institutes

The Grant Application Resource Center (GARC) provides standardized language and links to information to support the development of grant applications. Use this page to obtain information about the Institutes at the Icahn School of Medicine at Mount Sinai (ISMMS) to include in your proposals.

The Arnhold Institute for Global Health at Icahn School of Medicine at Mount Sinai designs, implements, tests, and supports the scaling of effective, equitable health systems solutions. Research efforts focus around identifying rigorous solutions for community health systems that demonstrate global reach. The Institute’s investigators engage in deep, collaborative partnerships in specific sites where they strive to advance multinational research, healthcare and educational opportunities. Their current collaborations include academic, government, community, and health systems partners in Nepal, Kenya, and New York City. The Institute’s research program operates in close concert with the Department of Health Systems Design & Global Health at the Icahn School of Medicine at Mount Sinai. The Department of Health Systems Design & Global Health was established in 2016 as the first in the nation to utilize the strength of a major U.S. health care system to learn from, and contribute to, global health systems. Under the direction of its Vice Chair for Research, Dr. Rachel Vreeman, MD, MS the Department unites faculty and staff with expertise in health services research, implementation science, chronic disease care models, health systems design, women’s health, pediatrics, infectious diseases, economic and policy analysis, and data science, to design and evaluate effective, equitable, global health systems solutions. Together, the Institute and Department aim to close the gap between evidence-based solutions and their real-world implementation at scale for the populations who would benefit the most.

Visit the Arnhold Global Health Institute for more information.

 

Last updated: March 2019

Mount Sinai’s strategic plan provides a road map for major investments in research and infrastructure to establish a series of new Institutes, including The Charles Bronfman Institute for Personalized Medicine (IPM).

The Institute is dedicated to advancing personalized health and health care with three core objectives

  • Provide clinical and translational investigators with greater and easier access to high quality, standardized biospecimen collections, linked with full clinical information.
  • Provide an academic research home and technology support for discovering clinically important genotype-phenotype associations through interdisciplinary, translational genomics programs.
  • Facilitate clinical development of gene-based diagnostics and risk assessment algorithms and evaluate their impact on health care delivery at the patient and population level.

IPM is home to research faculty pursuing studies in the clinical areas of pharmacogenomics, obesity and metabolic traits, cardiovascular and kidney disease. Institute faculty generates innovations and new paradigms in mapping of complex traits in diverse populations, clinical knowledge representation and phenomics, and personalized medicine clinical decision support.

Headed by Judy Cho,MD, IPM provides full and sole support for the IPM BioMe Biobank Program including the Biobank Informatics and Genomic Data Analysis Services Center (BIGDASC).

 

BioMe™ Biobank Program

To discover better treatments, researchers are seeking to unravel the complexity of disease at the most basic level through “molecular” studies. The donation of samples from tens of thousands of individuals is essential to such studies. BioMe is a biobank research program of the Charles Bronfman Institute for Personalized Medicine at Mount Sinai. BioMe is dedicated to advancing the application of human blood-derived biospecimen and clinical data to life science research to accelerate the development of personalized healthcare and medical solutions.

Since September 2007, over 47,000 Mount Sinai Health System patients have enrolled in the Electronic Medical Record-linked BioMe Biobank Program. It is designed to generate a large collection of DNA and plasma samples, and phenotypic (questionnaire-based and EMR-linked) and genomic data, that are stored in a way that protects patient’s privacy. The three major self-reported racial/ethnic populations include 32% EA (European Ancestry), 24% AA (African Ancestry, 35% HA (Hispanic Ancestry). At the same time, it enables research to be performed on de-identified, comprehensive, electronic clinical information extracted from the Mount Sinai Data Warehouse (MSDW).

More than 30,000 of the BioMe participants have genotype data available for genetic analyses. Data include whole exome sequencing, genome-wide genotyping array (GSA), and for a subset of participants (N~12,000) whole genome sequencing data is available.

IPM represents Mount Sinai as a member site to several large NIH-funded research networks, including the IGNITE Implementing GeNomics In pracTicE Network, Population Architecture Using Genomics and Epidemiology (PAGE), eMERGE II Network (electronic medical records and genomics), the eMERGE-Pharmacogenetics Research Network (PGRN) research partnership, the CKD Biomarker Consortium, the TOPMED (NHLBI Trans-omics for Precision Medicine) Program, GSP (NHGRI Genome Sequencing Program), among others.

The BioMe Biobank Program contributes under collaborative agreements with international research consortia and collaborations.

Visit the Charles Bronfman Institute for Personalized Medicine for more information.

 

Last update: March 2019

The mission of the Mindich Child Health and Development Institute (MCHDI) is to enable translational research of diseases affecting infants, children and adolescents by assembling outstanding physician-scientists and scientists in an intellectually rich and supportive environment, which fosters collaborative scientific investigation as well as the training of the next generation of scientific leaders for pediatric medicine.

The MCHDI is dedicated to translational research to better understand the pathogenesis of prevalent pediatric conditions and diseases in order to then develop and implement new treatment strategies. Leveraging Mount Sinai's leadership in genetics and genomics sciences as well as environmental medicine, the MCHDI has focused on the following areas of research emphasis to maximize its impact on new discoveries:

  • Asthma and Allergy
  • Cardiovascular Diseases
  • Neurodevelopmental Disorders
  • Obesity and Diabetes
  • Other Childhood Diseases

Visit the Mindich Child Health and Development Institute or contact Elena Lum for more information.

 

Last update: March 2019

The purpose of the Blavatnik Family Women's Health Research Institute is to optimize quality of care for women across the life span and to narrow gaps in treatment and outcomes in underserved populations.

As a research Institute, our focus will be to transform women's health by advancing science, training the next generation of scientific leaders in women's health, and promoting breakthroughs in clinical care.

Women make up more than half of the population in the United States. They use health care services more frequently than men do. And, women make most of the health care decisions for their families. However, while women live longer, they experience poorer health than men on a variety of outcomes. To date, too few institutions have established interdisciplinary research institutes dedicated to advancing science in the field of women’s health.

With the Blavatnik Family Women's Health Research Institute, Mount Sinai is filling that gap and taking a leadership role by leveraging existing faculty in several departments and institutes with overlapping research interests.

The Blavatnik Family Women's Health Research Institute aims to build and expand a research portfolio in key areas in women’s health, including:

  • Mental health and depression
  • Disparities and health equity research
  • Maternal and infant morbidity and mortality
  • Quality of care
  • Gynecological cancer
  • Reproductive endocrinology and infertility
  • LGBT health
  • Global health

The Blavatnik Family Women's Health Research Institute will facilitate collaborations across existing departments and institutes of the Icahn School of Medicine at Mount Sinai, leveraging and building on the existing strengths of the Mount Sinai Health System.

Visit the Blavatnik Women's Health Research Institute or contact Amy Balbierz for more information.

 

Last update: March 2019

ConduITS – the Institutes for Translational Sciences at Icahn School of Medicine at Mount Sinai (ISMMS). ConduITS was established in 2009 when ISMMS received a prestigious Clinical and Translational Science Award (CTSA) from the National Institutes of Health (NIH).  ConduITS was renewed for a second five-year term in 2015 with a $34 million grant. The CTSA Program of the National Center for Advancing Translational Sciences (NCATS) mission is to accelerate discoveries, development, and delivery of new treatments to improve health outcomes across the lifespan.

The award supports the ISMMS Institutes for Translational Sciences’ strategic plan to develop an infrastructure to support research and educate the next generation of investigators. ISMMS is one of 60 CTSA-funded hubs across the country. CTSA hubs are expected to streamline the research process to get studies up and running faster; to enhance collaborations with other hubs, community providers, patients, and industry; and to promote team science and develop effective methods for recruitment and retention of clinical research participants. ConduITS accomplishes this by:

  • Providing consultation, oversight, and facilities for clinical and translational research
  • Engaging the community and its affiliates to translate health benefits to the public
  • Developing new methodologies to improve trial design and reduce participant burden

ConduITS mission is to advance human health by transforming this hub into a translational research laboratory, partnering with our diverse patient population, other stakeholders, institutional clinicians and scientists, and investigators at other CTSA Network Hubs to ensure high quality research, research education, and development of unique, innovative resources to catalyze translation of biomedical discoveries across the lifespan.

We will accomplish this by achieving the following Specific Aims:

  1. Ensure that translational researchers have the skills and knowledge necessary to advance translation of discoveries by developing innovative curricula for high quality clinical and translational research training of students, investigators and research staff at all levels.
  2. Expand programs to further promote workforce diversity through recruitment, education, mentoring and retention of the most talented students, faculty and researchers,
  3. Foster a collaborative, collegial, transdisciplinary (shared) environment within our CTSA hub and the CTSA Network that includes incentives for formation of multi-disciplinary translational teams. We will also collaborate with other CTSA hubs to improve translational research.
  4. Coordinate the health care delivery and translational research enterprise by integrating secure electronic health records (EHRs), web-based clinical trials management systems and institutional databanks to better engage patients and community clinicians in clinical trials and community engaged research.
  5. Engage a diverse group of stakeholders at the local and national level in all phases of translational research, including patients, caregivers, clinicians, and healthcare delivery representatives, advocacy groups, NIH Institutes & Centers, other NCATS funded CTSA Hubs, biotech and pharmaceutical companies, and venture capital firms.
  6. Incorporate translational research across the lifespan with particular focus on pediatric research, geriatric populations, and special populations affected by health disparities.
  7. Continue to innovate and streamline research administrative oversight and processes to minimize roadblocks, identify and rectify gaps, ensure quality and assurance, monitor outcomes and garner feedback from stakeholders.

Any use of CTSA-supported resources requires citation of grant number UL1TR001433 awarded to ISMMS in the acknowledgment section of every publication resulting from this support. Adherence to the NIH Public Access Policy is also required. 

Visit ConduITS or contact the Office of Research Services for more information.

 

Last update: March 2019

Center for Therapeutic Antibody Development

Mission

The mission of CTAD is to collaborate with researchers in the design and development of monoclonal antibodies (mAb) for research and commercialization. Because of their sensitivity and specificity, mAb are critical basic science research tools and are the core technology for many diagnostic tests such as those used to verify pregnancy or influenza infection. In the past decade they have become the most successful new drug classification with yearly sales exceeding fifty billion dollars. If monoclonal antibodies are needed for basic science studies/grant submission, therapeutic or diagnostics use CTAD is available for a consultation to determine the best approach to producing the antibody of interest. If the antibody target has therapeutic value it is possible that it can be made in a humanized mouse system through collaborations with industrial partners.

Overview

The Center for Therapeutic Antibody Development (CTAD) has been in existence since 1996 under the guidance of Dr. Thomas Moran. The facility assists in all aspects of the generation of mAb from expressing the target protein to screening and purifying the selected clones. Hundreds of antibodies have been successfully generated for scientists at Mount Sinai as well as for other institutions. To date, over 30 monoclonal antibodies generated in the facility have been commercialized for basic science use.

Areas of Expertise

CTAD can assist in or perform any or all of the steps needed to generate high quality monoclonal antibodies for research or therapeutic use including:

  • Production of protein using various expression systems
  • Purification of protein
  • Immunization of appropriate host
  • Fusion and immortalization of B cell clones
  • Screening and selection of clones
  • Production of human monoclonal antibodies using mice from Regeneron Pharmaceuticals
  • Purification of antibodies
  • Mycoplasma testing

Protein expression and purification

CTAD has expert assistance available to prepare, purify and express proteins using methods that maximize native protein folding and stability. In most instances proteins can be produced when given only the genetic sequence of the protein.

Immunization and fusion

The CTAD has IACUC approval for the generation of hybridomas in mice, hamster and rat. Immunization protocols are selected according to the target immunogen and intended use of the antibody by the investigator. After fusion of B cells to an appropriate immortalized cell line, clones are selected and grown in semi-solid media.  Clones are picked and transferred to 96 well plates for screening and expansion of cells.

Screening

The selection of the screening method will be done through consultation with the investigator. Generally, the screening method is selected according to the assay of interest. If the priority for a successful antibody is use in flow cytometry, then flow is the most appropriate screening method. Other screens could include ELISA and functional screens. Screening can be done using a proxy antigen, which is a recombinant protein typically similar to the immunogen, or using the naturally expressed protein. All clones generated will be cryopreserved for storage for possible future applications.

Purification

Antibodies that pass the screening criteria are isotyped and may or may not go through a second type of screening. When the desired antibodies are identified, CTAD will expand the clone and purify the antibody preparations.

CTAD and Therapeutic monoclonal antibodies

Therapeutic monoclonal antibodies generated more than 50 billion dollars in sales last year. Six of the top 15 selling drugs in this country are monoclonal antibodies and Humera, a mAb specific for the cytokine TNF is now the largest seller at 9.5 billion.

There are more than 250 candidates currently in various stages of development/testing. CTAD is committed to developing monoclonal antibodies with potential use as therapeutics. Currently a number of collaborations between CTAD/Mount Sinai investigators and pharmaceutical or biotech companies are in progress.  Calls for targets that address unmet medical needs are released annually to encourage Mount Sinai investigators to work with CTAD to produce human antibodies with therapeutic potential using Regeneron human mice. Many of these projects are funded and the monoclonal antibodies produced are in various stages of licensing.

Last update: March 2019

 

Medicinal Chemistry Program

The Medicinal Chemistry Program of the Drug Discovery Institute is a resource available to basic and clinical research investigators at Mount Sinai who are interested in employing small molecule chemistry to furnish research probes or to develop new experimental small molecule therapeutics. Chemists in the Program operate in a newly renovated medicinal chemistry laboratory space located in the Icahn Medical Institute Building and in an environment conducive to interdisciplinary research, for example with biophysical (x-ray, NMR) and computational researchers; this capitalizes on existing strengths within Icahn School of Medicine.

To initiate the search for novel small molecule agents, research groups will run computational virtual screens in conjunction with the DDI’s Structure Based Drug Design Core and assay development with the Assay Development Core. Screening hits that are identified by the team will be available to work collaboratively with the research groups in three progressively more interdisciplinary phases:

  • Hit confirmation and resupply - Data from a screening campaign will be triaged to eliminate false positives or artifacts: compound purity from the active wells will be assessed, and material re-synthesized, scaled-up and purified. Hit compounds may then be interrogated in detail in the screening assay or other follow-up assays as appropriate to confirm useful levels of activity.
  • Hit to Lead Chemistry - Confirmed hits will then be assessed and ranked based on a number of factors in addition to potency, particularly chemical tractability. A chemically tractable lead will be of reasonably low molecular weight structure (<500 Da), which is amenable to rapid analog synthesis to facilitate exploration of structure activity relationships. Depending on the molecular type additional analogs may be available from commercial sources, or parallel libraries will be designed and synthesized to explore various sites for modification and improvement of the structure. A successful screening campaign will yield three or four tractable lead series suitable for this type for early exploration. Compound series where potency and selectivity can be usefully modulated will be characterized in more detail with respect to drug-like properties, and where appropriate with respect to predictive pharmacology models generated by the Systems Pharmacology Core (see the SPCC description for details). Medicinal chemists, together with biologists and pharmacologists will also work with Mount Sinai’s MSIP office to develop a strategy to define and protect intellectual property on novel composition of matter. In vitro leads of this type may serve as research tools for interrogation of novel disease targets or as jumping off points for further optimization.
  • Lead Optimization - Based on an assessment of biochemical potency, cell based activity, overall physicochemical profile and input from models from the SPBCC, one series may be selected for further optimization. The objectives of the lead optimization are to increase potency in cell-based assays and to test molecules in more downstream in vitro and in vivo functional assays. In vitro ADME parameters such as microsomal stability and physical properties such as aqueous solubility will be monitored as leads progress by outsourcing to appropriate contract research organizations (CRO). When an adequate balance of in vitro potency and physicochemical properties is achieved, initial in vivo rodent PK (IV, ip and oral) will be obtained at CROs.  At this stage in lead optimization broader pharmacological profiling of leads is appropriate: for example, selectivity profiling versus panels of receptors and enzymes. Early in vitro safety parameters may also be assessed at external collaborators, for example hERG channel or CYP450 activity. These assays may identify additional parameters that require optimization or influence go/no decisions on continued optimization; they will also provide input for model development by the SBDD on novel experimental therapeutics discovered at the institute.

Optimized leads produced by the DDI will have in vivo efficacy in animal models (either disease or biomarker), at an acceptable dose and route of administration, with no obvious toxicity or metabolic liabilities. Medicinal chemistry is central to the design and synthesis of these leads, and chemists will interact with scientists in the TCBC, SPBCC and PPC of the ETI as projects progress.

Visit the Medicinal Chemistry Core for more information or contact Robert J. DeVita, PhD for more information.

Last update: March 2019

 

Structure-Based Drug Discovery

(formerly Molecular Informatics Core)

The Structure-Based Drug Discovery (SBDD) facilitates sophisticated use of molecular structure information by providing access to databases, state-of-the-art software, and expert support for protein sequence and structure analysis, protein structure modeling, characterization of protein-ligand interactions, and virtual screening. The SBDD staff assists researchers with the development and execution of computational strategies to address specific research questions. Working closely with other core facilities of the Experimental Therapeutics Institute (ETI) at Mount Sinai, in particular the Integrated Screening Core, the SBDD will support target characterization, lead discovery, and lead optimization.

Target characterization services include: protein structure modeling for target proteins, identification and prioritization of ligand binding sites in protein structures, and modeling of protein-ligand complexes. In the area of lead discovery, the SBDD offers small-molecule virtual screening and docking, including high-throughput computational screening of small-molecule libraries, containing more than 4,000,000 compounds, against experimental and predicted target protein structures; construction of targeted libraries for HT chemical screening based on virtual screening results; targeted docking of selected compounds into experimental and predicted target protein structures. For lead optimization the SBDD offers services to model and characterize protein-ligand interactions, identification of affinity and selectivity determining residues in the target protein, and support for structure-based refinement of protein-ligand interactions to enhance affinity and selectivity.

Visit Structure-Based Drug Discoveryfor more information or contact Roberto Sanchez, PhD.

Last update: March 2019

 

Pluripotent Stem Cell Core Facility

The study of human embryonic stem cells (hESCs) and Induced Pluripotent Stem Cells (iPSCs) and its differentiation into specific lineages provides an extraordinary opportunity to study the cellular / molecular mechanisms regulating pluripotency and differentiation. It also offers a potentially unlimited source of numerous cell types for drug screening and cell-based therapies. The Pluripotent Stem Cell Core has been established to facilitate the transfer of this technology to the Mount Sinai community and other institutions. The objectives of this facility are:

  1. To generate induced pluripotent stem cells using the latest transgene-free Sendai Virus and mRNA/micro RNA technology. For more information please visit Services
  2. To provide undifferentiated PSCs, mouse embryonic fibroblasts (MEFs) and/or hematopoietic, cardiac and endoderm progenitors. For more information please visit Getting Started
  3. To train faculty, postdoctoral fellows and students in the maintenance and the differentiation of pluripotent stem cells. For more information please visit Services
  4. To provide tested media / reagents necessary for the maintenance as well as the differentiation of pluripotent stem cells at discounted prices. For more information please visit Supply Center
  5. To karyotype and bank hESC and iPSC stocks. For more information please visit Core Stem Cell Stock
  6. To generate gene targeted hESC / iPSC lines. For more information please visit Services
  7. To assist PIs with pilot hESC / iPSC projects. For more information please visit Services

 

Induced Pluripotent Stem Cells (iPSCs)

Recent developments in the field have demonstrated the ability to reprogram adult human cells to an ES cell-like state using only 3 or 4 defined genes. This allows the derivation of patient-specific hiPSC lines without the major ethical barriers associated with transfer of adult cell nuclei into oocytes. Therefore, a part of the core will be dedicated to assist investigators with the development of novel iPSC lines and their differentiation.

For funding purposes, it is important to acknowledge the Pluripotent Stem Cell Core in all publications that include data derived from the facility.

For more information contact Sunita D'Souza, PhD.

Last update: March 2019

 

Assay Development and Screening

The Assay Development and Screening Core provides assay development and medium to high throughput screening service to all investigators at Icahn School of Medicines and outside corporations.

Our core also provides extensive consultation and technical assistance for user-initiated and executed projects, including support for assay design, automation and data analysis. 

Our integrated resources include:

  • More than 50,000 newly invested small diversified compounds from Life Chemicals
  • More than 110,000 Diver-Set and CNS-Set small compounds from ChemBridge.
  • More than 8.000 macrocycles from ChemBridge.
  • Both human and mouse Mission siRNA/shRNA libraries from Sigma-Aldrich.
  • Two automatic liquid handling systems, Janus Integrator Platform and hp D300 Dispenser, which are able to handle samples from milliliters to picoliters.
  • Two plate readers, FLIPRtetra plus with 384-channel head and EnVision with whole sets of filters for reading different plates.
  • ImageXpress Ultra system, which is able to perform medium to high throughput content screens.

Our core is also able to screen small molecule and siRNA/shRNA libraries in both cell-based and cell-free formats. Targets could be GPCRs, ion channels, enzymes and others.  Besides primary screening, we support early hit cytotoxic studies and basic cardiosafety tests.

Last update: March 2019

The Friedman Brain Institute is an interdisciplinary hub for defining the mechanisms underlying brain and nervous system diseases and for translating those findings into preventative or restorative interventions. The Institute is focused on three major areas of investigation where Mount Sinai can be truly transformative: neural injury and repair, cognition, and neuropsychiatry. The Institute will be judged by its success in advancing brain repair, developing new ways to advance cognition, and improving the treatment of neuropsychiatric disorders.

The Brain Institute's work spans basic molecular and genetic research of nervous system disorders, from animal models to investigations of human populations in the clinic. New knowledge from animal studies will drive clinical investigations, while new insight from clinical studies will help guide more basic exploration into the underlying mechanisms. This broad-based approach incorporates a wide range of state-of-the-art methodologies and coordinates efforts among numerous departments at the Icahn School of Medicine, including neuroscience, neurology, psychiatry, neurosurgery, pharmacology, geriatrics, ophthalmology, and rehabilitative medicine.

Mount Sinai has been recognized as a leader in brain research and treatment for over a century. It has been at the forefront of the rapidly evolving discipline of basic neuroscience, while its longstanding reputation for excellence in clinical neurology, neurosurgery, psychiatry, ophthalmology, and rehabilitative medicine has continued to grow.

Visit the Friedman Brain Institute or contact Jenny Rivera for more information.

Last Update: March 2019

The Global Health and Emerging Pathogens Institute is the nucleus of Mount Sinai's work on infectious diseases and the pathogens that cause them. The Institute, based in New York City, builds on Mount Sinai’s internationally recognized expertise in RNA virus research and encompasses ongoing research on the molecular pathogenesis of influenza, HIV, and dengue and Ebola viruses, as well as on hepatitis C and West Nile.

The innate component of the immune response is a rapid one, in which the body recognizes and fights off general classes of infectious agents. Mount Sinai has been at the forefront of current research, identifying viral factors that inhibit innate immune responses and showing how such factors contribute to the pathogenesis of the virus. Global Health and Emerging Pathogens Institute expertise in virology will prove invaluable as we work to develop robust vaccines and antiviral drugs that save people lives.

The Global Health and Emerging Pathogens Institute is focused on expanding Mount Sinai’s world-renowned programs in RNA viruses. Our strategy serves as a model for developing new programs to study other viruses particularly zoonotic and emerging viruses, including MERS and Zika viruses. These viruses blur the line between animal and human viruses and do not respect country borders, consistent with the concept "one world, one health, one medicine", linking human, animal and environmental health. The Institute is also developing research programs driven by local and global public health needs. One emerging area of interest is the impact of host genetics and of the microbiome in virus disease.

Visit the Global Health and Emerging Pathogens Institute or contact Adolfo Garcia-Sastre, PhD for more information.

Last Updated: March 2019

The Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (PrIISM) is a new entity that encompasses and integrates disease-focused immunological research programs and cutting-edge technology centers. PrIISM is working to better understand the fundamental mechanisms used by immune cells to promote disease progression and response to treatment, developing and implementing novel technologies to better diagnose and guide treatment of disease, and generating new therapies to modulate the immune system in a broad spectrum of diseases, including cancer, inflammatory, cardiovascular, and neurological diseases.

Technology includes the Human Immune Monitoring Center and the Microbiome Translational Center.

The Graduate School of Biomedical Sciences at Icahn School of Medicine is ranked among the very best in the world for academic training and the Precision Immunology Institute at Icahn School of Medicine at Mount Sinai (PrIISM) is dedicated to establishing a world-class immunology graduate program. The goal of the Immunology Training Area is to provide students interested in immunology with a rigorous and flexible program. Students will be given the individual intellectual and technical skills required to become outstanding scientists in the field of immunology. Students benefit from the multidisciplinary nature of our graduate program and take additional credits that could be in any area of interest to them and may include topics in microbiology, cancer, genetics, system biology, and genomic sciences among others. In addition, graduate students will also participate in an Immunology Journal Club, Work in Progress, and Seminar Series. Laboratory rotations and research training allows students to rotate and select any of the multiple laboratories that are currently working in immunology.

 

The Human Immune Monitoring Center

The HIMC provides comprehensive immune monitoring services for clinical and translational studies based on the highest standard operating systems. It has a staff of 15 highly skilled and trained lab scientists and technicians. It also has a quality assurance specialist that oversees equipment maintenance and protocol compliance. HIMC personnel is a team of experts specialized in immune profiles of disease and analysis of immune testing and response. Specifically, they provide standardized immune assays including: CyTOF mass cytometry, Single cell RNA sequencing, immune phenotyping, multiplex immunohistochemistry, antigen specific T cell assays, antibody profiling, seromics, Luminex multiplex assay and cytokine detection, in a cost-effective manner. For the HTARC HIMC will be in charge of storage and management of samples collected at ISMMS and storage of all samples from JHU and MSKCC that will be analyzed by CyTOF and RNAseq (Including Single cell RNAseq and Bulk seq).

 

Good Laboratory Practice facility

This state-of-the-art facility offers patient specimen processing and storage using electronic sample management and tracking systems. HIMC is currently operating with SOPs to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of laboratory procedures. Equipment and facilities are appropriate for the procedures being performed, with all equipment maintained, operated, and calibrated at regular intervals according to written SOPs. Personnel receive training in all procedures performed, which are documented in their individual training records and repeated as needed. All procedures have written SOPs that are strictly adhered to with any deviations and corrective actions taken properly documented. Procedure worksheets capture all critical information including signature or initials of the person performing the procedure. Worksheets are reviewed by QA and archived in the appropriate binders. All of these requirements will ensure the reliability of the results generated by the HIMC and provide all the resources necessary for the completion of this project.

 

Throughput

The HIMC can handle very large numbers of samples and studies thanks to the implementation of robust SOPs for every aspect of operations, under Laboratory Integration Management Systems (LIMS) described in Attachment I. To illustrate capacity, in 2016, there were 49 active clinical trials or studies, representing a monthly average of 85 patient specimen collection visits, generating 4531 monthly bio-specimen aliquots tracked by barcode for storage and analysis. These samples were analyzed for a monthly average of 91 nucleic acid isolation, 45 multiplex and ELISA assay, 17 immune cell enrichments and sorting, 24 seromics or grand serology assays, 36 ELISPOT assays, 50 flow cytometry samples, 100 CYTOF samples, and 30 multiplex IHC. Samples include cells and plasma from peripheral blood, bone marrow, tissue suspensions from multiple tissues sites (healthy tissues and tumor lesions), stool, purified DNA/RNA/protein material, and pathology slides. HIMC follows Good Laboratory Practices (GLP) as well as Good Documentation Practices (GDP), as detailed in Attachment I.

 

Data Meetings

HIMC meets weekly on Tuesday morning with all staff for data review and continuous training. In addition, HIMC holds weekly meetings on Wednesday’s at noon and co-organizes with the Immunotherapy program a lecture series on Mondays with external speakers to educate the community.

 

Equipment

The HIMC laboratory space consists of about 1,200 sq. ft. of space located on the 5th and 6th floors of the Hess building at ISMMS and is equipped with two third generation HELIOS mass cytometry analyzers from Fluidigm equipped with a SuperSampler fluidics system to facilitate large volume sample acquisitions of millions of cells, NanoZoomer S60 slide scanner for pathology slides, a LSRFortessa BD special order analytical flow cytometer (5 lasers) with high throughput capability (96 well format) to support large clinical study analysis, a RoboSep for magnetic bead based cell separation/isolation, a Luminex 200 System capable of multiplexing up to 41 analytes simultaneously in a single microtiter plate well, a Chromium™ 10x Single Cell Controller to encapsulate single cells and generate scRNAseq data after library preparation, a QiaCube and a Qia Symphony machine for automated nucleic acid isolation, two tissue culture rooms dedicated for patient sample processing and to perform immune function assays, 3 laminar hoods, 4 tissue culture incubators, centrifuges (two Eppendorf 5425R and 5810R), and sample bar coding facility and sample management/tracking via Freezerwork server maintained by Mount Sinai. Freezerworks is utilized for storing, tracking, annotating and managing all tissue-fluid specimens including their derivatives (e.g. slides, DNA, RNA). Specimens are stored in two -80 REVCO's both with emergency back-up systems. HIMC also has shared equipment ownership of an Axon Autoloader 4200AL microarray scanner with GenePix Pro software (Molecular Devices) for Seromics assays, a Biotek ELx405 Microplate Washer fitted with a Biostack Multiplate Stacker for washing steps of ELISA and ELISPOT, a Biotek Synergy L Microplate Fluorescence Reader also fitted with Biostack Multiplate Stacker for ELISA, and a 4-color flow cytometer FACSCalibur™ (BD Biosciences) for simple flow cytometry. The following equipment is available on the same floor as HIMC and is shared with the Tisch Cancer Institute: Bio-Rad Molecular Imager Gel Doc XR, Li-Cor Odyssey Infra-Red imaging system, NanoDrop spectrophotometer. Lab spaces also include microscopes, balances, centrifuges, biosafety cabinets, incubators, liquid nitrogen and freezer banks, and automated pipetters for high-throughput handling. In addition to the equipment above, the HIMC has also acquired a commercial Multiplexed Ion Beam Imaging (MIBI) Tissue Analyzer (Ionpath) analogous to the instrument at Stanford with delivery expected in April 2018. This mass spectrometry based imaging platform that permits up to 100 targets (proteins, DNA and RNA) to be measured simultaneously on a single tissue section with resolution surpassing light microscopy. The presence of a this second MIBI, in addition to the one at Stanford, will help build capacity as the Atlas progresses.

 

Microbiome Translational Center

The Microbiome Translational Center (MTC) in the Precision Immunology Institute of the Icahn School of Medicine at Mount Sinai (PrIISM) serves as a central resource hub for basic and translational microbiome research. The MTC compromises of a team of experts in microbiology, gnotobiotics and microbiome research including computational analysis and provides expert advice on experimental design and innovative approaches to microbiome research. The MTC is directed by the facility director Dr. Bongers and its two faculty directors, Drs. Faith and Clemente. The MTC operates with a five-member technical staff with a combined experience of >30 years. The center facilitates translational microbiome discoveries by providing investigators with appropriate sample collection SOPs, digitized sample biobanking, and various downstream microbiome assays including, high-throughput microbial nucleotide isolation, preparation of 16S amplicon and shotgun metagenomics libraries using a Beckman liquid handling robotic, Illumina MiSeq/HiSeq sequencing, and computational analysis. The MTC also houses a state-of-the-art automated anaerobic culture facility for rapid isolation of microbes that includes quick strain identification using a MALDI Biotyper. We also maintain a biorepository of >1000 human microbiome samples and a bank of longitudinal reference microbiome material that are used to validate if assays are within set operational compliance criteria and all experiments are recorded into an electronic LabArchives Research notebook.

The gnotobiotic mouse facility of the MTC accommodates up to 10 large gnotobiotic breeding isolators (210 cages) and maintains a daily census of approximately 600 animals. In addition, it can support up to 12 smaller experimental gnotobiotic isolators for individual experiments including those with defined consortia of bacteria and custom diets. Additionally, 96 positive pressure cages and up to 150 outside-the-isolator cages can be used to screen gnotobiotic mice with different community compositions. The gnotobiotic facility maintains a colony of vasectomized Swiss-Webster males for rederivation of new germ-free lines by embryo transfer in collaboration with the Mouse Genetics and Gene Targeting core at Mount Sinai, and over half of the lines maintained in our facility were rederived in-house with the remainder coming from existing gnotobiotic facilities across the United States. Mouse colonies are tracked in our custom web-based mouse tracking software and database. All germ-free quality control metrics are stored in a web-based digital platform available to the facility operators and maintained in perpetuity.

Visit the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (PrIISM) or contact Miriam Merad, MD, PhD for more information.

 

Last Update: March 2019

The Icahn Institute for Data Science and Genomic Technology is a first-of-its-kind institute dedicated to:

  • Harnessing global biomedical data to predict novel therapies.
  • Developing technologies to profile disease and test novel therapies.
  • Rapidly translating novel therapies to benefit patients faster than has ever been possible.

The Icahn Institute’s core values are founded in the belief that disrupting the pace of biomedical discovery and translational medicine requires doing science differently, with world leading data scientists, technology innovators, and disease experts working as one team to bring the idea of bench to bedside to life.

In conjunction with Mount Sinai’s Precision Medicine Initiative, the Icahn Institute is designed to radically accelerate the pace of therapeutic innovation through the integration of large-scale data analysis generated by advanced genomic technologies.

Visit The Icahn Institute for Data Science and Genomic Technology for more information.

 

Last update: March 2019

Mission
The Institute for Medical Education (IME) was established in 2001 to promote and advance innovative medical education and scholarship as well as recognize and reward our outstanding educators. The IME serves the vital need in our institution of creating, educating, mentoring, and retaining the best educators for our students, residents, and faculty. Fostering the success of our educators includes recognizing and rewarding those who display dedication and excellence in their work and providing programs that develop and reinforce their scholarship, teaching skills, and successful promotion. In doing so, we create a network of dedicated educators that contributes its knowledge and experience back to this community by serving as teachers and mentors. Our activities have positioned the Institute as a center for teaching and learning excellence across the Mount Sinai health system.

Goals
The scope of the IME goals encompasses promoting scholarship and dissemination of innovative medical education approaches, acknowledging and rewarding our accomplished educators, creating faculty development opportunities for all teaching faculty and supporting career advancement of medical educators in academia. Specifically, the IME aims to:

  • Recognize and reward excellence in education and teaching
  • Facilitate the academic promotion of educators
  • Support skills development in teaching, learning and medical education research
  • Promote the dissemination of innovative medical education scholarship
  • Create an educational community whose members inform and support one another

Visit the Institute for Medical Education or contact Robert Fallar, PhD for more information about the Institute for Medical Education.

Last Update: March 2019

The Institute for Translational Epidemiology, headed by Emanuela Taioli, MD, PhD, takes advantage of Mount Sinai's extraordinary strengths in both research and clinical practice to establish a strong program in epidemiologic research that connects to clinical, basic, and applied research programs within the Mount Sinai Health System. Our vision is to advance interdisciplinary and patient-oriented research and to contribute to translational and integrative research at the School of Medicine. The Institute is committed to expanding the role of epidemiology in clinical research, and the presence of several world-class clinical and research programs makes ISMMS an ideal setting to establish a strong epidemiology research program to complement existing clinical and preventive activities. New concentration areas will build on existing clinical and research strengths in Chronic Disease Epidemiology, Infectious Disease Epidemiology, Mental Health, Occupational Epidemiology, Epidemiologic Methods, Life Course Epidemiology, and Molecular and Genetic Epidemiology. Training, education, and health inequalities will be part of the research portfolio.

Epidemiology Research

Epidemiologic research has successfully identified the main lifestyle and environmental risk factors associated with chronic diseases. One important finding of epidemiologic research on chronic diseases is that many features are shared between different types of diseases. Risk factors such as tobacco use, obesity, and environmental pollutants contribute to the etiology of different groups of chronic diseases. But the main tools of epidemiologic research, such as prospective cohort studies, are also ideally suited to study several chronic outcomes in parallel.  A major challenge of epidemiologic research rests in the elucidation of the separate and combined effects of genetic, biochemical, and lifestyle risk factors of chronic diseases and outcome determinants.

In recent years, the emphasis in epidemiologic research has shifted from etiologic to outcome research. With the introduction of novel, ground-breaking therapeutic approaches, based on recent discoveries in immunology and genetics, researchers are now well positioned to study the effect of these therapies on long-term survival and quality of life. It is also important to assess if appropriate treatment is equally administered to all the patients in need for such treatment, or if the same racial/ethnic disparities observed in disease prevention and early detection persist in disease treatment. In this way, epidemiologic research is addressing the growing interest in racial/ethnic/gender disparities in health and healthcare delivery.

Another key area of epidemiologic research is the comparative effectiveness of alternative treatments in real-life settings, where patients suitable for treatment belong to a variety of ages and races, have a spectrum of comorbidities, and differ in insurance coverage. Evaluating therapeutic approaches in such diverse segments of the population offers insights on the translation of new discovery science into clinical practice.

The Institute collaborates closely with the Department of Population Health Science and Policy and the Department of Preventive Medicine, as well as a variety of other Mount Sinai entities in building the research portfolio. In addition, training and education is part of the research portfolio.

Visit the Institute for Translational Epidemiology for more information.

 

Last Update: March 2019

The mission of the Icahn School of Medicine Mount Sinai Diabetes, Obesity and Metabolism Institute (DOMI) is to develop better therapeutic and prevention strategies for Types 1 and 2 diabetes, obesity, diabetes, and the metabolic syndrome through basic and clinical research.

Ten areas form the core missions of the Metabolism Institute's research enterprise:

  1. Drug Discovery to Enhance Pancreatic Beta Cell Regeneration and Replacement.
  2. Reversing the Immunopatholobiology of Types 1 and Type 2 Diabetes, in collaboration with the Precision Immunology Institute.
  3. Understanding the Genetics and Genomics of Diabetes, in collaboration with the Institute for Genomics and Multiscale Biology and the Charles Bronfman Institute for Personalized Medicine.
  4. Enhancing Understanding of Intermediary Metabolism and Signal Transduction in skeletal muscle, liver, the pancreatic beta cell and the adipocyte.
  5. Defining CNS Control of Metabolism in the adipocyte, liver and beta cell via the sympathetic nervous system.
  6. Addressing the Vascular, Renal, and Neuropathic Complications of Diabetes. 
  7. Supporting Clinical Research in Type 1 Diabetes, Type 2 Diabetes, Obesity and Bariatric Surgery in collaboration with the Mount Sinai CTSA.
  8. Supporting The Artificial Pancreas program, the largest in New York City.
  9. Elucidating The Cancer-Diabetes Interface.
  10. Supporting Community Based Prevention, Diabetes Research and Epidemiology.

Research Cores available to the Diabetes, Obesity and Metabolism Institute include mouse metabolic and histopathologic phenotyping, Seahorse metabolic evaluation, high-throughput drug discovery, human and animal metabolomics, calorimetry, imaging, cell biological imaging, proteomics, next-gen sequencing, epigenomics, bioinformatics, monoclonal antibody generation, microsurgery, among many others.

Finally, we share an NIH/NIDDK-supported joint Albert Einstein College of Medicine and Mount Sinai Diabetes Research Center (ES-DRC), with multiple cores, including a Human Islet and Adenoviral Core (HIAC) based at Mount Sinai.

Visit the Diabetes, Obesity and Metabolism Institute for more information.

 

Last Update: March 2019

As one of the largest and most comprehensive adult and pediatric abdominal transplantation centers in the world, the Recanati/Miller Transplantation Institute (RMTI) at The Mount Sinai Health System is committed to outstanding patient care, research, and educational programs. Our transplant services for adults and children include kidney, liver, pancreas, and intestinal organ transplant. In addition, RMTI has one of the largest living donor programs in the United States. Through our Zweig Family Center for Living Donation, we provide the best in medical, surgical, and psychological care to living organ donors. Additionally, we provide comprehensive, personalized treatment and compassionate care to people with a wide variety of liver/bile duct and pancreatic diseases, including cancers affecting these organs.

We bring together a distinguished team of surgeons, physicians, and other healthcare professionals to support patients with end stage disease in every step of their care up to and including transplantation. RMTI team members view transplantation as one step in the continuum of patient care. Our multidisciplinary approach ensures that patients benefit from the expertise of multiple specialists, who understand their unique needs.

Having performed more than 5,500 liver, kidney, pancreas, and intestinal transplants over 40 years, we have a rich history of innovation and excellence in the field of organ transplantation. One of the key factors in our success is close collaboration between our physicians and the scientists who conduct state-of-the-art research here. It enables us to provide leading-edge technologies and the most up-to-date therapies to our patients, including individuals with complex medical needs. For example, RMTI researchers working side-by-side with our clinical teams have made great strides in increasing the eligibility of patients previously denied kidney / pancreas transplants due to medical conditions, such as Hepatitis B, Hepatitis C, and HIV.

At RMTI, we offer a full spectrum of abdominal organ transplantation programs and services, including: adult and pediatric liver disease and transplantation, adult and pediatric kidney transplantation, adult pancreas transplantation and intestinal rehabilitation and transplantation.

Visit the Recanati/Miller Transplantation Institute or contact Carolyn Forman for more information.

 

Last update: March 2019

The Tisch Cancer Institute (TCI) was awarded National Cancer Institute (NCI) designation in 2015. The mission of the TCI, under the leadership of Ramon Parsons, MD, PhD, is to advance the field of cancer research, treatment and prevention and to facilitate the availability of these advancements to our communities so as to extend and improve the lives of cancer patients and their families.

To accomplish this mission, the TCI has four research programs: Cancer Immunology, which addresses anti-tumor immunity and fosters the development of cancer vaccines; Cancer Mechanisms, which seeks to understand the biology of cancer cell development; Liver Cancer, whose focus is to discover novel approaches to diagnose and treat liver cancer; and Cancer Prevention and Control, which addresses the important aspects of primary and secondary cancer prevention.  Cancer Institute members span across multiple departments in the medical center and work collaboratively within and across these multidisciplinary research programs.  In 2018, cancer grant awards exceeded $56 million in direct costs.

As part of its mission, the Tisch Cancer Institute supports several Shared Resources and Facilities that are critical to cancer research. These include Cancer Biostatistics, Flow Cytometry, Mouse Genetics and Microscopy, as well as important specialized facilities such as the Hematological Malignancies Tissue Bank, the Human Immune Monitoring Core, and the Vaccine and Cellular Therapy Lab.

To facilitate cancer clinical research, the Tisch Cancer Institute provides oversight of all cancer clinical trials through its Protocol Review and Monitoring Committee and its Cancer Clinical Trials Office.  In 2018, there were 230 open therapeutic cancer clinical trials that enrolled a total of 463 new patients.

In addition, the TCI provides competitive Research Awards to basic, clinical, and population cancer scientists to facilitate new insights into cancer biology, prevention and treatment.

Visit the Tisch Cancer Institute or contact Sharon Mias for more information.

 

Last update: March 2019

The Translational and Molecular Imaging Institute (TMII) serves as a research catalyst for a new generation of translational and molecular imaging methodologies. It offers researchers highly efficient, cost-effective services for commonly used imaging tests, without the usual institutional overhead. TMII provides expertise for developing and validating new procedures and encourages interdisciplinary collaborations that help close the gaps between clinical and preclinical studies. Through its targeted seminars, research fellowships, publications, and other training programs, TMII educates researchers, postdoctoral fellows, students, and technicians about biomedical imaging advances and options.

TMII is responsible for coordinating and executing all in vivo imaging research at Mount Sinai. Currently, TMII has over 50 members with expertise in all aspects of translational imaging research, from image acquisition to image analysis. Mount Sinai and TMII have entered into a strategic partnership with Siemens Medical Systems to support its effort in translational research. Housed in approximately 20,000 square feet in the new Hess Center for Science and Medicine, are state-of-the-art Siemens systems, including:

  • 7T MRI - whole body, actively shielded human scanner.
  • PET/MR(3T) mMR system - fully integrated, simultaneous, multi-modal, whole body scanner.
  • 3T MRI Skyra - wide bore whole body scanner.
  • Somatom Force CT - dual-source for faster and lower dose imaging.

These systems are available for human and large animal research. In addition, TMII has access to a variety of Siemens systems that are managed by the Department of Radiology at Mount Sinai but accessible for research thru TMII, including a 1.5T MR Aera scanner, a PET/CT(40) Biograph mCT, and a multidetector CT Somatom Definition Flash.

TMII also provides preclinical imaging services performed on a variety of small animal scanners including:

  • 9.4T (89mm bore size) Bruker vertical bore scanner.
  • 7.0T (154mm bore size) Bruker horizontal bore scanner.
  • Biophotonic IVIS spectrum.
  • Micro ultrasound Vevo 2100 from VisualSonics.
  • Micro PET/CT w/ sub-half mm3 PET volumetric resolution

All of these imaging systems are equipped with a variety of peripherals for physiological monitoring, physiological gating, fMRI experiments, drug infusion and anesthesia delivery.

TMII has a data center in the new Center for Science and Medicine that contains a dedicated server room hosting a larger Mac Server Cluster of 2 x 16TB of initial online storage with direct connectivity to all of the imaging modalities. TMII XNAT serves as the central point for research data transfer, archive, and sharing. TMII XNAT is built upon a secure database, supports automated pipelines for processing managed data, and provides tools for exploring the data. Currently TMII XNAT runs on two mirrored Linux servers with 60TB storage space on each. It can host more than 15,000 image sessions with backups.  In addition, TMII offers an image analysis room equipped with a large viewing display and more than 15 high-performance workstations to facilitate learning and image analysis as well as a nanomedicine laboratory for the design, synthesis and evaluation of novel imaging probes and drug delivery systems.

Visit the Translational and Molecular Imaging Institute or email TMII for more information.

 

Last update: March 2019